Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ph-797804. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 20/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 1/20 | 1.00 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ph-797804 SCHEMBL29527304 | 1.00 | MAPK14 (1.00) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| Ph-797804 SCHEMBL29351545 | 1.00 | MAPK14 (1.00) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6473101 | 0.95 | MAPK14 (0.90) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL12798295 | 0.95 | MAPK14 (0.90) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4376166 | 0.94 | MAPK14 (1.00) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL20883147 | 0.94 | MAPK14 (0.88) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29593337 | 0.94 | MAPK14 (1.00) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL5862955 | 0.93 | MAPK14 (1.00) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4381593 | 0.92 | MAPK14 (0.87) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29594382 | 0.92 | MAPK14 (0.87) | MAPK14ROCK2MAPK12MAPK11STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| EP-3478322-B1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LTD (GB) | 2020-12-30 | — | — | EP | claimed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| EP-3478322-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | hVIVO Services Limited (GB) | 2019-05-08 | — | — | EP | claimed |
| US-20180369220-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-B SIGNALS, AND APPLICATION THEREOF | THE DOSHISHA (JP) | 2018-12-27 | — | — | US | claimed |
| EP-3381472-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF- SIGNALS, AND APPLICATION THEREOF | The Doshisha (JP) | 2018-10-03 | — | — | EP | claimed |
| WO-2014025315-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-02-13 | — | — | WO | claimed |
| WO-2013055297-A1 | METHOD FOR PREPARING MESENCHYMAL STEM CELL-LIKE CELLS AND CARDIOMYOCYTE-LIKE CELLS | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2013-04-18 | — | — | WO | claimed |
| EP-2102161-B1 | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide | PFIZER PROD INC (US) | 2012-05-02 | — | — | EP | claimed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | claimed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | claimed |
| EP-2102161-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | Pfizer Products Incorporated (US) | 2009-09-23 | — | — | EP | claimed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | claimed |
| WO-2008072079-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PRODUCTS INC. (US) | 2008-06-19 | — | — | WO | claimed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885ROCK2 332/4885MAPK12 12/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885ROCK2 761/4885MAPK12 50/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885ROCK2 332/4885MAPK12 12/4885 |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | CYP4X1, CYP4B1, KDM4B | MAPK14 2841/4885ROCK2 1833/4885MAPK12 2027/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885ROCK2 353/4885MAPK12 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.